Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922609 | 0.90 | GPR119 (0.64) | GPR119PDE3BPDE3AMAOAMAOB | |
| SCHEMBL1990355 | 0.90 | MAOA (0.47) | GPR119PDE3BPDE3ADRD2MAOA | |
| SCHEMBL429773 | 0.85 | HRH3 (0.55) | GPR119CHEK2 | |
| SCHEMBL31718484 | 0.81 | MAOA (0.61) | PDE3BPDE3ADRD2MAOAMAOB | |
| SCHEMBL1990653 | 0.81 | MAOB (0.49) | PDE3BPDE3ADRD2MAOAMAOB | |
| SCHEMBL14124585 | 0.79 | GRIN2D (0.48) | PDE3BPDE3A | |
| SCHEMBL12601013 | 0.79 | MAOB (0.52) | PDE3BPDE3ADRD2MAOAMAOB | |
| SCHEMBL26668458 | 0.79 | SLC2A1 (0.59) | GPR119CHEK2SLC2A1 | |
| SCHEMBL15545122 | 0.79 | CRBN (0.44) | GPR119PDE3BPDE3AMAOAMAOB | |
| SCHEMBL27040152 | 0.78 | CRBN (0.59) | GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| EP-2512241-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Neurop, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075537-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | NEUROP, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075537-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | NEUROP, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | GRIN2A, GRIN2B, GRIN2C | GPR119 410/4885CHEK2 3064/4885PDE3B 3939/4885 |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | NR2C2, GRIN2C, CNR1 | GPR119 612/4885CHEK2 3480/4885PDE3B 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.